

Company Profile

Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Executive Board



Matthias Gärtner,
CEO



Falk Neukirch,
CFO




Christoph Prusseit,
CBO¹ Germany




Constantijn van Rietschoten,
CBO¹ International


Structure and Segments




FY² 2024 EBITDA pre³ split⁴



Consolidated Revenue in €m



Consolidated EBITDA pre³ in €m



¹CBO= Chief Business Officer ² Full Year; ³adjusted for extraordinary expenses (EBITDA pre);⁴ Including the segment "Services" (-13% in FY 2024); CAGR = Compound Annual Growth Rate

Contact:
ir@medios.group
www.medios.group

Key Figures

in €m	2024 (IFRS)	2023 (IFRS)	Change
Revenue	1,883.0	1,784.7	+5.5%
EBITDA pre*	79.0	60.5	+30.5%
Margin in %	4.2	3.4	+23.5%

*adjusted for extraordinary expenses

Basic Information

Share Capital	€25,505,723
No. of shares	25,505,723
Share class	No-par value bearer shares
WKN/ISIN	A1MMCC/DE000A1MMCC8 / DE000A409682**
Trading places	Regulated Market Frankfurt (Prime Standard)

** Note pursuant to Sec. 7 German Stock Exchange Admission Regulation (Börsenzulassungsverordnung – BörsZulV): From a capital increase in kind registered with the commercial register on June 11, 2024, 1,700,000 newly issued shares came into existence, which bear a separate ISIN (DE000A409682) and are currently not admitted to trading.


Shareholder Structure

All figures according to voting rights notifications of the notifying parties

54.8%

Free float

- 4.9% Paladin Asset Management investment stock corporation with variable capital and sub-funds
- 4.7% SEB Investment Management AB



19.7%

Martin Hesse

incl. attribution of
BMSH GmbH

15.1%

Luxempart Invest S.á.r.l.

6.7%

Bencis Capital Partners B.V.

3.9%

Treasury shares

Share Price in €

